Drug data last refreshed 15h ago · AI intelligence enriched 6d ago
ALEVE PM is a fixed-dose combination of naproxen sodium (a nonsteroidal anti-inflammatory drug) and diphenhydramine hydrochloride (a first-generation antihistamine with sedating properties) for oral use. It is indicated for the temporary relief of minor aches and pains due to headache, muscular aches, backache, minor arthritis pain, menstrual cramps, and the common cold, with the added benefit of nighttime sleep aid. The naproxen provides anti-inflammatory analgesia while diphenhydramine promotes sleep onset.
Product is at peak lifecycle stage with moderate competitive pressure (30), indicating a mature brand team focused on market share defense and optimization rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on ALEVE PM offers career exposure to OTC brand management, consumer marketing, and mature-market strategy within Bayer's portfolio. This is a established brand with stable market positioning, making it suitable for professionals seeking to develop deep expertise in brand optimization, retail channel management, and defensive competitive strategy.
Worked on ALEVE PM at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo